NORTHBROOK, Ill., Feb. 16, 2012 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, today reported financial results for the fourth quarter and full year ended December 31, 2011.
Revenues for 2011 were $2.5 million compared to $2.0 million for 2010. Product sales increased from $1.4 million for fiscal 2010 to $2.4 million for fiscal 2011, driven by an increase in consumables revenue and system sales.
William Moffitt, Nanosphere's president and chief executive officer, said, "We shipped 30 systems to new customers during the fourth quarter demonstrating an inflection point has been reached in our business. The investments we have made in menu expansion, particularly in the microbiology market segment, have generated significant customer interest and demand."
Costs and operating expenses decreased from $43.4 million in 2010 to $38.0 million in 2011, driven by a reduction in litigation defense and settlement expenses related to a patent dispute settled in 2010. Costs and operating expenses in the fourth quarter 2011 were $9.5 million compared to $10.0 million in the third quarter 2011.
Net loss for 2011 was $35.4 million as compared with $40.6 million in 2010. Net loss for the fourth quarter of 2011 was $8.6 million as compared with $7.4 million for the same period in 2010 and $9.5 million in the third quarter of 2011.
Cash flow in the fourth quarter and third quarter of 2011 was negative $7.6 million. Cash at December 31, 2011 was $39.3 million.
Conference Call Details
The company will hold a live conference call and webcast for investors on Thursday, February 16, 2012 at 10:00 A.M., Eastern Time. The teleconference can be accessed by dialing 888-713-4216 (U.S./Canada) or 617-213-4868 (international), participant code 64723995. The call will also be broadcast live over the Internet and can be accessed by interested parties at the Investor Relations tab on the Nanosphere website: www.nanosphere.us. For interested individuals unable to join the call or webcast, a replay will be available through February 23, 2012 by dialing 888-286-8010 or for international calls 617-801-6888, pass code 40788890, or on the company's website.
About Nanosphere, Inc.
Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene® System, for direct genomic and ultra-sensitive protein detection. This easy to use and cost effective platform enables simple, low cost and highly sensitive genomic and protein testing on a single platform. Nanosphere is based in Northbrook, IL. Additional information is available at http://www.nanosphere.us.
The Nanosphere, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4344
Except for historical information, the matters discussed in this press release are "forward-looking statements" and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the following: (i) Nanosphere's ability to develop commercially viable products; (ii) Nanosphere's ability to achieve profitability; (iii) Nanosphere's ability to produce and market its products; (iv) Nanosphere's ability to obtain regulatory approval of its products; (v) Nanosphere's ability to protect its intellectual property; (vi) competition and alternative technologies; and (vii) Nanosphere's ability to obtain additional financing to support its operations. Additional risks are discussed in the Company's current filings with the Securities and Exchange Commission. Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
| Nanosphere, Inc. | |||
| Statements of Operations | |||
| (dollars and shares in thousands except per share data) | |||
| Years Ended December 31, | |||
| 2011 | 2010 | 2009 | |
| REVENUE: | |||
| Product sales | $2,433 | $1,416 | $1,124 |
| Grant and contract revenue | 100 | 610 | 1,090 |
| Total revenue | 2,533 | 2,026 | 2,214 |
| COSTS AND EXPENSES: | |||
| Cost of sales | 1,820 | 2,597 | 2,175 |
| Research and development | 20,013 | 18,821 | 18,608 |
| Sales, general, and administrative | 16,154 | 22,007 | 14,472 |
| Total costs and expenses | 37,987 | 43,425 | 35,255 |
| Loss from operations | (35,454) | (41,399) | (33,041) |
| OTHER INCOME (EXPENSE): | |||
| Foreign exchange gain (loss) | (13) | 4 | (4) |
| U.S. Treasury grant | — | 978 | — |
| Interest expense | — | (274) | (1,258) |
| Interest income | 48 | 79 | 354 |
| Total other income (expense) | 35 | 787 | (908) |
| NET LOSS | $ (35,419) | $ (40,612) | $ (33,949) |
| Net loss per common share – basic and diluted | $ (.94) | $ (1.46) | $ (1.46) |
| Weighted average number of common shares outstanding – basic and diluted | 37,800 | 27,755 | 23,302 |
| Nanosphere, Inc. | ||
| Balance Sheets | ||
| (dollars in thousands) | ||
| As of December 31, | ||
| 2011 | 2010 | |
| Cash and cash equivalents | $ 39,273 | $ 39,628 |
| Other current assets | 3,434 | 3,299 |
| Total current assets | 42,707 | 42,927 |
| Net property and equipment | 4,522 | 5,142 |
| Intangible assets - net of accumulated amortization | 3,033 | 3,231 |
| Other assets | 75 | 75 |
| Total assets | $ 50,337 | $ 51,375 |
| Total liabilities | 4,728 | 6,851 |
| Total stockholders' equity | 45,609 | 44,524 |
| Total liabilities and stockholders' equity | $ 50,337 | $ 51,375 |